Cryoport (CYRX) Announces Appointment of Linda Baddour to its Board of Directors

March 3, 2021 4:36 PM EST

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced its Board of Directors has elected Linda Baddour as a member of the Board, effective March 15, 2021. Linda Baddour is a senior executive with over twenty years of experience in healthcare, life sciences and pharmaceuticals.

"Our corporate governance underpins all that we do at Cryoport and we are delighted to strengthen our Board as we leverage our newly expanded global footprint and advanced temperature-controlled supply chain platform to spur our growth," said Jerrell Shelton, CEO of Cryoport.

"Linda's deep healthcare experience gained from her leadership role scaling PRA Health Sciences, a global contract research organization and data science company, will be a valuable addition to our Board of Directors," added Dr. Ram Mandalam, Chairman of the Nominating and Governance Committee.

Linda Baddour stated, "Cryoport's reputation as a provider of innovative, high quality and reliable temperature-controlled supply chain solutions for the life sciences has made it a clear leader in the life sciences industry, and especially within the Biopharma/Pharma market. There are currently an increasing number of regenerative therapies that are entering development, progressing through clinical trials and approaching commercialization and Cryoport has a unique opportunity to achieve outsized growth by scaling its operations within this rapidly growing market. It is an incredibly exciting time to join Cryoport and I look forward to bringing my experience to the Board to help drive forward this strategy."

Ms. Baddour has served on the Board of Directors of Waters Corporation, a publicly traded analytical laboratory instrument and software company, since 2018 as well as two Genstar Capital portfolio companies, Advarra since 2019 and Signant Health, since 2020. From 2007 to 2018, Ms. Baddour served as Executive Vice President and Chief Financial Officer of PRA Health Sciences, a global contract research organization and data science company. During Ms. Baddour's tenure, PRA Health Sciences grew from approximately 3,000 employees to over 17,000. From 1995 to 2007, Ms. Baddour worked at Pharmaceutical Product Development, Inc., serving as Chief Financial Officer, Treasurer and Chief Accounting Officer. Ms. Baddour earned both a B.A. and M.B.A. from the University of North Carolina at Wilmington and is a certified public accountant.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Board Changes

Related Entities

Earnings